权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

BLR&D Research Career Scientist Award

BLR

基本信息

批准号：
10265377
负责人：
WAEL EL-RIFAI
金额：
--
依托单位：
MIAMI VA HEALTH CARE SYSTEM
依托单位国家：
美国
项目类别：
财政年份：
2017
资助国家：
美国
起止时间：
2017-04-01 至 2022-03-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/10265377
关键词：
17q 20q Acids Africa Animal Model Anti-Inflammatory Agents Antioxidants Area Asia Award Barrett Esophagus Barrett&apos s Tumorigenesis Barrett&apos s carcinogenesis Basic Science Belief Bile fluid Bioinformatics Biological Bone Marrow Transplantation Cancer Biology Cancer Center Cancer Etiology Cellular biology Cessation of life Chronic Clinical Clinical Oncology Clinical Research Clinical Trials Collaborations DARPP DNA Damage DNA Methylation DNA Sequence Alteration Detection of Minimal Residual Disease Development Disease Distal Doctor of Medicine Doctor of Philosophy Drug resistance ERBB2 gene Epidermal Growth Factor Receptor Epigenetic Process Esophageal Adenocarcinoma Esophagus Europe Event Exposure to Faculty Far East Fluorescent in Situ Hybridization Funding Gastric and esophageal adenocarcinomas Gastroenterology Gastroesophageal reflux disease General Population Genes Genetic Goals Health Helicobacter Infections Helicobacter pylori Hematologic Neoplasms Home Human Human Resources In Situ Hybridization In Vitro Incidence Individual Inflammation Inflammatory Response Institution International Journals Knockout Mice Laboratories Latin America Link Location Malignant Neoplasms Malignant neoplasm of esophagus Malignant neoplasm of gastrointestinal tract Mediating Mentors Metaphase Metaplasia MicroRNAs Middle East Military Personnel Molecular Molecular Cytogenetics Mus NF-kappa B National Cancer Institute Oncogenes Oncogenic Oncology Operative Surgical Procedures Outcome Oxidative Stress Pathology Patients Peer Review Phase I/II Clinical Trial Positioning Attribute Postdoctoral Fellow Publications Publishing Radiation Oncology Reflux Relapse Research Research Activity Research Personnel Research Training Resistance Risk Risk Factors Role STAT3 gene Sampling Scientist Signal Transduction Soldier Solid Neoplasm Stomach Stomach Carcinoma Surgical Oncology TFF1 gene TP53 gene Testing Therapeutic Time Tissue Sample Training Translational Research Tumor Suppression Tumor Suppressor Genes Tumor Suppressor Proteins United States National Academy of Sciences Universities Veterans Work World Health Organization anticancer research antioxidant enzyme aurora kinase A beta catenin cancer genetics carcinogenesis career chemotherapy comparative genomic hybridization epidemiologic data epigenomics experience follow-up functional genomics gastric tumorigenesis gastrointestinal global health glutathione peroxidase graduate student high risk histone methylation human tissue in vitro Assay inhibitor/antagonist interdisciplinary approach interest malignant stomach neoplasm medical schools meetings melanoma member military veteran mouse model next generation sequencing novel novel strategies overexpression oxidative DNA damage pre-clinical programs promoter recruit research and development response statistics targeted treatment tool tumor tumorigenesis undergraduate student upper gastrointestinal cancer

项目摘要

Project Summary/Abstract Dr. El-Rifai has a long standing track record in the molecular studies of cancer. He has established strong national and international collaborations for the studies of gastric and esophageal cancer. His laboratory provides unique training experiences in diverse areas of cancer research that include molecular mechanisms of tumorigenesis and drug resistance. Dr. El-Rifai's laboratory works closely with basic science (Cell biology, Cancer Biology, Statistics, Bioinformatics) and clinical Departments (Pathology, Oncology, Radiation Oncology, Surgery, Gastroenterology) for one common goal; a better clinical outcome. The laboratory has a long-standing interest in functional genomics and IntegrOmics (integrated omics) in upper GI cancers using animal models, human samples, and in vitro studies. Dr. El-Rifai leads a competitively NCI-funded research program in upper GI cancers. Dr. El-Rifai has made significant contributions in the area of gastric cancer, Barrett's esophagus and esophageal adenocarcinoma. His major research interests are in genetics, epigenetics, and cancer biology, focusing on gastrointestinal tumorigenesis and the development of novel strategies for cancer therapeutics. Dr. El-Rifai's research encompasses animal models as tools for identification of tumor development and progression. Dr. El- Rifai discovery and translational research utilize next generation sequencing, DNA and histone methylation, and miRNAs studies. He has been successful in identifying the signaling links between inflammation and cancer in gastric and esophageal adenocarcinomas, discovering novel genes that mediate drug resistance, and developing targeted therapy approaches for upper GI cancers. His work using the trefoil factor 1 knockout mouse model in conjunction with in vitro assays and human tissues samples has shown that TFF1 has potent anti-inflammatory and tumor suppressor functions, which protect against H. pylori-mediated development of gastric cancer in mouse and human. Dr. El-Rifai lab has made significant contributions to our understanding of the molecular mechanisms underlying the development and progression in Barrett's carcinogenesis. Barrett's esophagus, the main risk factor for esophageal adenocarcinoma, develops as a consequence of chronic gastroesophageal reflux disease where the distal esophagus becomes abnormally exposed to acid and bile refluxate from the stomach. The pioneering work from his lab has shown that DNA methylation wipes out the expression of several protective antioxidant enzymes, important for protecting against reflux-induced oxidative stress and DNA damage, thereby facilitating progression of metaplastic Barrett's esophagus to esophageal cancer. His studies aim to understand the molecular basis of tumorigenesis to identify and characterize targets that regulate signaling network hubs and important biological features of carcinogenesis. His laboratory pre-clinical work has been instrumental in moving some targets such as Aurora kinase A to phase I/II clinical trials in melanoma and upper GI cancers. As the director of Surgical Oncology Research, Dr. El-Rifai oversees the research development, mentors junior faculty, and participates in research training of residents and fellows in Vanderbilt, VA, and Meharry Medical College. Dr. El-Rifai has trained more than 50 personnel that included undergraduate and graduate students, postdocs, and residents. He has mentored more than 15 junior faculty members, many of whom have progressed to independent faculty positions. Cancer is a disease with no boundaries; therefore, Global Health initiatives that rely on multi-disciplinary approaches are crucial for defeating cancer. As such, Dr. El-Rifai's laboratory collaborates with several academic institutions and cancer centers worldwide that span Europe, Africa, Asia, and Latin America. Dr. El-Rifai has a firm belief that clinical and translational research founded on strong basic science discoveries is the way to win our battle against cancer.

项目总结/文摘